🌐 Investor Relations | Effervescence DX

Why Invest in Effervescence DX

• Differentiated Technology: Smartphone-enabled diagnostics with real-time AI analysis

• Market-Ready Innovation: Focus on hepatitis C, HIV, PFAS detection, fentanyl detection, and field-deployable disease and containment monitoring

• Scalable Platform: Adaptable microfluidic cartridge + universal smartphone reader

• Global Health & Commercial Potential: Aligned with health equity, harm reduction, and public health priorities

About Effervescence DX

Effervescence DX is redefining the future of diagnostics through AI-powered, smartphone-integrated, microfluidic technology. Our compact, cost-effective platform enables accurate point-of-care testing for infectious diseases (HCV, HIV), substance detection, and environmental health in real-world settings — no lab required.

We are building a world where healthcare diagnostics are accessible, portable, and effortless — for everyone, everywhere.

🏆 Milestones & Recognitions

Effervescence DX is proud to have earned the trust and support of leading institutions and initiatives:

• Babson College SUD Sprint 2024 – Pitch Final Presentation Award -UMass Lowell M2D2 – In-Kind Lab Space Award

• VentureWell Ocean Technology Cohort – Stage 0 Accelerator (Customer Discovery and Coaching)

• NIAID ITEP Program – Commercialization and SBIR Preparation Training

• NIH RADx Initiative Funding –awarded to the Shafiee Lab at Brigham and Women’s Hospital (BWH) to support the development of Next Generation Diagnostic Technology
  Awarded $500,000 in funding to accelerate the creation of the VISTA diagnostic platform

Strategic Partnerships and Supporters

• Brigham and Women’s Hospital / Harvard Medical School

• VentureWell

• Babson College SUD Sprint

• MassGeneral Hospital

• UMass Lowell

• NIH/NIAID

• Gener8

Let’s Build the Future of Diagnostics Together
We are seeking funding partners to accelerate:

• Regulatory approvals (CLIA-waiver, FDA submissions)

• Field validation and clinical pilots

• Manufacturing scale-up

• Commercial launch and licensing expansion

For investor materials or to connect: [effervescencedx@gmail.com]